The antianginal agent, ranolazine, reduces myocardial infarct size but does not alter anatomic no-reflow or regional myocardial blood flow in ischemia/reperfusion in the rabbit

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 13, Issue 3, 2008, Pages 226-232

  Hale, Sharon L ^a,b   Kloner, Robert A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b GOOD SAMARITAN HOSPITAL   (United States)

Author keywords

Infarct size; No reflow; Rabbit; Ranolazine; Regional myocardial blood flow

Indexed keywords

ANTIANGINA PECTORIS AGENT; DIRECT YELLOW 7; FLUORESCENT DYE; RANOLAZINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG MECHANISM; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE BLOOD FLOW; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ACETANILIDES; ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR AGENTS; CORONARY CIRCULATION; DISEASE MODELS, ANIMAL; HEART RATE; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; NO-REFLOW PHENOMENON; PIPERAZINES; RABBITS;

EID: 49749093088     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/1074248408320278     Document Type: Article

References (24)

1. Jain D., Dasgupta P., Hughes LO, Lahiri A., Raftery EB Ranolazine (RS-43285): a preliminary study of a new anti-anginal agent with selective effect on ischaemic myocardium. Eur J Clin Pharmacol. 1990 ; 38: 111-114.
2. Thadani U., Ezekowitz M., Fenney L., Chiang Y. -K; for the Ranolazine Group. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina. Circulation. 1994 ; 90: 726-734.
3. Rousseau MF, Pouleur H., Cocco G., Wolff AA Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol. 2005 ; 95: 311-316.
4. Pepine CJ, Wolffe AA ; for the Ranolazine Group. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Am J Cardiol. 1999 ; 84: 46-50.
5. Chaitman BR, Skettino SL, Parker JO, et al.; for the MARISA Investigators. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004 ; 43: 1375-1382.
6. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. A randomized controlled trial. JAMA. 2004 ; 291: 309-316.
7. Fraser H., Belardinelli L., Wang L., Light PE, McVeigh JJ, Clanachan AS Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts. J Mol Cell Cardiol. 2006 ; 41: 1031-1038.
8. Belardinelli L., Shryock JC, Fraser H. The mechanism of ranolazine action to reduce ischemia-induced diastolic dysfunction. Eur Heart J. 2006 ; 8 (Suppl A). A10 - A13.
9. Wang P., Fraser H., Lloyd SG, McVeigh JJ, Belardinelli L., Chatham JC A comparison between ranolazine and cvt-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion. J Pharmacol Exp Ther. 2007 ; 321: 213-220.
10. Manciet LH, Poole DC, McDonagh PF, Copeland JG, Mathieu-Costello O. Microvascular compression during myocardial ischemia: mechanistic basis for no-reflow phenomenon. Am J Physiol. 1994 ; 266: H1541 - H1550.
11. Kloner RA, Ganote CE, Jennings RB The "no-reflow" phenomenon following temporary coronary artery occlusion in the dog. Clin Invest. 1974 ; 54: 1496-1508.
12. Hale SL, Leeka JA, Kloner RA Improved left ventricular function and reduced necrosis after myocardial ischemia/reperfusion in rabbits treated with ranolazine, an inhibitor of the late sodium channel. J Pharmacol Exp Ther. 2006 ; 318: 418-423.
13. Rasband WS Image J. Bethesda, MD: National Institutes of Health ; 1997-2007. http://rsb.info.nih.gov/ij/
14. Imahashi K., Kusuoka H., Hashimoto K., Yoshioka J., Yamaguchi H., Nishimura T. Intracellular sodium accumulation during ischemia as the substrate for reperfusion injury. Circ Res. 1999 ; 84: 1401-1406.
15. Murphy E., Cross H., Steenbergen C. Sodium regulation during ischemia versus reperfusion and its role in injury. Circ Res. 1999 ; 84: 1469-1470.
16. Noble D., Noble PJ Late sodium current in the pathophysiology of cardiovascular disease: consequences of sodium-calcium overload. Heart. 2006 ; 92: iv1 - iv5.
17. Undrovinas A., Fleidervish, Makielski JC Inward sodium current at resting potentials in single cardiac myocytes induced by the ischemic metabolite lysophosphatidylcholine. Circ Res. 1992 ; 71: 1231-1241.
18. Wu J., Corr PB Palmitoyl carnitine modifies sodium currents and induces transient inward current in ventricular myocytes. Am J Physiol. 1994 ; 266: H1034 - H1046
19. Ward CA, Giles WR Ionic mechanism of the effects of hydrogen peroxide in rat ventricular myocytes. J Physiol. 1997 ; 500 (Pt 3). 631-642.
20. Ambrosio G., Weisman HF, Mannisi JA, et al. Progressive impairment of regional myocardial perfusion after initial restoration of postischemic blood flow. Circulation. 1989 ; 80: 1846-1861.
21. Reffelmann T., Hale SL, Li G., et al. Relationship between no reflow and infarct size as influenced by the duration of ischemia and reperfusion. Am J Physiol. 2001 ; 282: H766 - H772.
22. Allely MC, Alps BJ Prevention of myocardial enzyme release by ranolazine in a primate model of ischaemia with reperfusion. Br J Pharmacol. 1990 ; 99: 5-6.
23. Zacharowski K., Blackburn B., Thiemermann C. Ranolazine, a partial fatty acid oxidation inhibitor, reduced myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol. 2001 ; 418: 105-110.
24. Black SC, Gralinski MR, McCormack JG, Driscoll EM, Lucchesi BR Effect of ranolazine on infarct size in a canine model of regional myocardial ischemia/reperfusion. J Cardiovasc Pharmacol. 1994 ; 24: 921-928.